Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells

被引:0
|
作者
Lee, Keun-Wook
Kim, Jee Hyun
Park, Jung-Hyun
Kim, Hwang-Phill
Song, Sang-Hyun
Kim, Sang Gyun
Kim, Tai Young
Jong, Hyun-Soon
Jung, Kyung Hae
Im, Seock-Ah
Kim, Tae-You
Kim, Noe Kyeong
Bang, Yung-Jue
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[5] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea
关键词
SK-7041; histone deacetylase inhibitor; lung cancer; breast cancer; apoptosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A class of synthetic histone deacetylase (HDAC) inhibitors, which are hybrids of trichostatin A and MS-275 were previously developed. In this study, the antitumor effects of SK-7041, one of those novel HDAC inhibitors, was evaluated on lung and breast cancer cell lines. Materials and Methods: Human lung and breast cancer cells, as well as normal human bronchial epithelial (NHBE) cells were treated with SK-7041, and results were compared with those of cells treated with suberoylanilide hydroxamic acid (SAHA). Results: SK-7041 induced time-dependent histone hyperacetylation and showed more potent cytotoxicity than SAHA in cancer cells. These antiproliferative effects of SK-7041 were due to apoptotic cell death caused by G21M-phase arrest and to a lesser extent to G1 arrest. Moreover, SK-7041 inhibited cancer cell proliferation more selectively than NHBE cell proliferation. Conclusion: These results suggest that SK-7041 may have potential anticancer activity.
引用
收藏
页码:3429 / 3438
页数:10
相关论文
共 50 条
  • [21] Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells
    Janyst, Karolina
    Janyst, Michal
    Siernicka, Marta
    Lasek, Witold
    ONCOLOGY REPORTS, 2018, 39 (04) : 1999 - 2005
  • [22] Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid
    Shi, Xiumin
    Li, Min
    Cui, Meizi
    Niu, Chao
    Xu, Jianting
    Zhou, Lei
    Li, Wei
    Gao, Yushun
    Kong, Weisheng
    Cui, Jiuwei
    Hu, Jifan
    Jin, Haofan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (03): : 600 - +
  • [23] In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer
    Rephaeli, A
    Blank-Porat, D
    Tarasenko, N
    Entin-Meer, M
    Levovich, I
    Cutts, SM
    Phillips, DR
    Malik, Z
    Nudelman, A
    INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (02) : 226 - 235
  • [24] Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
    Chandra R Tate
    Lyndsay V Rhodes
    H Chris Segar
    Jennifer L Driver
    F Nell Pounder
    Matthew E Burow
    Bridgette M Collins-Burow
    Breast Cancer Research, 14
  • [25] Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor
    Zuco, Valentina
    Cassinelli, Giuliana
    Cossa, Giacomo
    Gatti, Laura
    Favini, Enrica
    Tortoreto, Monica
    Cominetti, Denis
    Scanziani, Eugenio
    Castiglioni, Vittoria
    Cincinelli, Raffaella
    Giannini, Giuseppe
    Zunino, Franco
    Zaffaroni, Nadia
    Lanzi, Cinzia
    Perego, Paola
    BIOCHEMICAL PHARMACOLOGY, 2015, 94 (02) : 79 - 90
  • [26] Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
    Tate, Chandra R.
    Rhodes, Lyndsay V.
    Segar, H. Chris
    Driver, Jennifer L.
    Pounder, F. Nell
    Burow, Matthew E.
    Collins-Burow, Bridgette M.
    BREAST CANCER RESEARCH, 2012, 14 (03)
  • [27] Anti-breast Cancer Effects of Histone Deacetylase Inhibitors and Calpain Inhibitor
    Mataga, Megan A.
    Rosenthal, Shoshana
    Heerboth, Sarah
    Devalapalli, Amrita
    Kokolus, Shannon
    Evans, Leah R.
    Longacre, Mckenna
    Housman, Genevieve
    Sarkar, Sibaji
    ANTICANCER RESEARCH, 2012, 32 (07) : 2523 - 2529
  • [28] Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells
    Jain, PT
    Rajah, TT
    Pento, JT
    ANTI-CANCER DRUGS, 1997, 8 (10) : 964 - 973
  • [29] The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
    Butler, Lisa M.
    Liapis, Vasilios
    Bouralexis, Stelios
    Welldon, Katie
    Hay, Shelley
    Thai, Le M.
    Labrinidis, Agatha
    Tilley, Wayne D.
    Findlay, David M.
    Evdokiou, Andreas
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) : 944 - 954
  • [30] Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells
    Louis, M
    Rosato, RR
    Battaglia, E
    Néguesque, A
    Lapotre, A
    Grant, S
    Bagrel, D
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (06) : 1569 - 1574